Mirae Asset Global Investments Co. Ltd. Has $1.23 Million Holdings in LifeStance Health Group, Inc. (NASDAQ:LFST)

Mirae Asset Global Investments Co. Ltd. decreased its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 34.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 156,585 shares of the company’s stock after selling 81,566 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in LifeStance Health Group were worth $1,226,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of LifeStance Health Group in the third quarter valued at approximately $206,000. Brown Advisory Inc. acquired a new stake in LifeStance Health Group in the 3rd quarter valued at $28,140,000. WESPAC Advisors LLC bought a new stake in LifeStance Health Group during the 3rd quarter worth about $90,000. Jennison Associates LLC boosted its stake in shares of LifeStance Health Group by 35.4% during the 3rd quarter. Jennison Associates LLC now owns 2,046,358 shares of the company’s stock worth $14,058,000 after buying an additional 535,358 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of LifeStance Health Group by 4.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,895,887 shares of the company’s stock valued at $26,765,000 after acquiring an additional 168,091 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Stock Performance

Shares of NASDAQ LFST opened at $5.87 on Tuesday. LifeStance Health Group, Inc. has a 12 month low of $4.74 and a 12 month high of $9.59. The stock has a 50 day moving average of $6.48 and a 200-day moving average of $6.54. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $2.23 billion, a P/E ratio of -11.51 and a beta of 1.34.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $263.14 million. LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. As a group, equities research analysts predict that LifeStance Health Group, Inc. will post -0.3 EPS for the current year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Kevin Michael Mullins sold 115,136 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the transaction, the insider now directly owns 4,575,480 shares of the company’s stock, valued at approximately $36,695,349.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Kevin Michael Mullins sold 115,136 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $8.02, for a total value of $923,390.72. Following the transaction, the insider now owns 4,575,480 shares of the company’s stock, valued at $36,695,349.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paula Cipollone sold 13,996 shares of LifeStance Health Group stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $6.93, for a total value of $96,992.28. Following the sale, the insider now directly owns 293,562 shares of the company’s stock, valued at $2,034,384.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 245,463 shares of company stock valued at $1,786,868. Company insiders own 8.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on LFST. The Goldman Sachs Group upped their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Monday, March 4th. Morgan Stanley reissued an “overweight” rating and issued a $10.00 price objective on shares of LifeStance Health Group in a report on Monday. Barclays raised their target price on shares of LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Thursday, February 29th. Finally, Jefferies Financial Group upped their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, LifeStance Health Group currently has a consensus rating of “Hold” and a consensus target price of $8.83.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.